APR

Capricor Therapeutics is a biotechnology company that develops therapies for cardiovascular and muscular diseases, including its Duchenne muscular dystrophy treatment.

Why it’s in the news: It is in the news because its Duchenne muscular dystrophy drug is facing an expected rejection from the FDA.

Latest on APR

• Opinion: Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study
• STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection
• ASEAN headlines India's export expansion in April-June quarter
• Brasil | Comissão aprova regra sobre uso de dados por inteligência artificial
• Social intrapreneurs can change the world too
• Q1 Results Today Live: Veranda Learning posts mixed Q1, TMPV shares gain ahead of Q1 results today, Page Industries, Solar Ind, LG Electronics, Max Healthcare, GIC, Godrej, Jubilant Foodworks, Amber Enterprises, Indraprastha, Brigade, JSW Cement, Honasa to announce Q1 results

Connections

2 entities linked to APR across the news graph.